Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve

HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity ...

Full "IntellAsia: Resources" article